• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21721 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2012     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Rotavirus vaccination - a health technology assessment]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ropeginterferon alfa-2b (polycythaemia vera) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Romosozumab (osteoporosis) - Addendum to Commission A20-24]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Romiplostim (Nplate) and eltrombopag (Revolade) for the treatment of immune thrombocytopenic purpura]
2012     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Role of PET/CT with choline analogue radiotracers in the diagnosis and staging of prostate cancer]
2015     Finnish Office for Health Care Technology Assessment (Finohta) [Role of fractional exhaled nitric oxide (FeNO) measurement in the management of asthma with corticosteroids]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rolapitant (prevention of nausea and vomiting in chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2017     Agenzia nazionale per i servizi sanitari regionali (Agenas) [Robotic surgery]
2010     Andalusian Health Technology Assessment Area (AETSA) [Robotic surgery using the da Vinci robotic telemanipulation system in hysterectomy]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Robotic surgery in benign and malignant surgical pathology (urology, general and digestive surgery, cardiothoracic surgery, gynecology, endocrinology, ophthalmology, and head and neck surgery). Chapter II: urological, gynecological, general and digestive surgery]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Robotic surgery in benign and malignant surgical pathology (urology, general and digestive surgery, cardiothoracic surgery, gynecology, endocrinology, ophthalmology, and head and neck surgery). Chapter I: cardiothoracic, endocrine, ophthalmological surgery, and head and neck surgery]
2011     The Regional Health Technology Assessment Centre (HTA-centrum) [Robotic surgery for benign gynecologic disease]
2010     Andalusian Health Technology Assessment Area (AETSA) [Robotic surgery by means of the da Vinci robotic telemanipulation system in general and digestive surgery]
2010     Andalusian Health Technology Assessment Area (AETSA) [Robotic surgery by means of the da Vinci robotic telemanipulation system in cardiovascular surgery]
2024     Norwegian Institute of Public Health (NIPH) [Robotic hysterectomy]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Robotic gynecological surgery]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Robotic Bronchoscopy for Lung Nodule Diagnostics. Horizon Scanning Technologies]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Robotic assisted laparoscopic surgery for cervical and endometrial cancer]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Robot-assisted surgery: a systematic review of effectiveness and safety for elected indications and accumulating costs]
2010     Andalusian Health Technology Assessment Area (AETSA) [Robot-assisted surgery using da Vinci robot telemanipulation in prostatectomy]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Robot-assisted rehabilitation for incomplete spinal cord injury]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted rectal resection for rectal cancer]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted prostatectomy for prostate cancer]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Robot Assisted Radical Prostatectomy (RARP)]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Robot assisted orthopaedic surgery]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Rivastigmine for delirium in intensive care patients, a double-blind, randomised placebo-controlled add-on trial]
2006     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Rituximab in patients with rheumatoid arthritis:systematic review and economic evaluation]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Rituximab for the treatment of patients with chronic lymphocytic leukemia]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Rituximab for the treatment of chronic immune thrombocytopenic purpura]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Rituximab for patients with diagnosed chronic neuromyelitis, myasthenia gravis and chronic inflammatory demyelinating polyneuropathy]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Rituximab biosimilars]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Risk-reducing surgery in BRCA1 or 2 mutation carriers]
2022     Austrian Institute for Health Technology Assessment (AIHTA) [Risk-based breast cancer screening in Austria: a systematic analysis of predictive models to assess individual breast cancer risk, their utility and applicability in a breast cancer screening programme]
2007     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Risk-adjustment in health services evaluation]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Risk factors at the regional level for suicide in the Korean elderly]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Risk factor analysis and probability of fragility fracture in a cohort of women with bone densitometry indication]
2019     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Risk and needs assessment regarding reoffending in adolescents]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Risdiplam in spinal muscular atrophy]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risdiplam (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risdiplam (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risdiplam (spinal muscular atrophy, < 2 months) – Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (plaque psoriasis) - Second Addendum to Commission A19-41]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (plaque psoriasis) - Addendum to Commission A19-41]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (Crohn disease) – Addendum to Commission A22-133]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ripretinib (gastrointestinal stromal tumour (GIST)) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Riociguat for inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension after surgical treatment]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Riociguat (pulmonary arterial hypertension in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Riociguat (PAH) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Riociguat (CTEPH) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Riociguat - Assessment according to § 35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Riluzole in amyotrophic lateral sclerosis]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rilpivirine (new therapeutic indication): addendum to commisison A15-55]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rilpivirine (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rilpivirine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2020     National Committee for Technology Incorporation (CONITEC) [Rifapentine plus isoniazid for treatment of latent mycobacterium tuberculosis infection (LTBI)]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer) - Addendum to Commission A17-45]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer; combination with fulvestrant) - Addendum to Commission A19-06]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer; combination with an aromatase inhibitor) - Addendum to Commission A19-06]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer, combination with fulvestrant) - Addendum to commission A20-22]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer, combination with an aromatase inhibitor) - Addendum to commission A20-21]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Rheumatoid arthritis - health technology assessment of diagnosis and treatment]
2011     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [ReWalk(tm): motorized orthosis in wheelchair users paraplegic people]
2010     Committee for New Health Technology Assessment (CNHTA) [Revolix 70]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Revision of the information materials on colorectal cancer screening]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Review process of matricial requirements for acute care facilities in the Quebec traumatology network]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Review on the medical and health economic evidence for an inclusion of colposcopy in primary screening programs for cervical cancer]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Review on the medical and health economic evidence for an inclusion of colposcopy in primary screening programs for cervical cancer]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the study protocol and statistical analysis plan on routine practice data collection for onasemnogene abeparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV) - Addendum to commission A20-61]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the study protocol and statistical analysis plan on routine practice data collection for onasemnogene abeparvovec - Second addendum to Commission A20-61]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the study protocol and statistical analysis plan on routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV) - Addendum to commission A21-130]
2010     Basque Office for Health Technology Assessment (OSTEBA) [Review of the psychological treatment in first psychotic episode]
2014     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Review of the indications of stereotactic body radiation therapy (SBRT) in patients with primary tumours and oligometastases]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the final study protocol and statistical analysis plan on routine practice data collection for onasemnogene abeparvovec - Third addendum to Commission A20-61]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Review of the evidence on the impact of school closures through the evolution of the COVID-19 pandemic]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Review of the efficacy of drug treatment for neuropathic pain]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Review of the efficacy of drug treatment for neuropathic pain (2nd edition)]
2014     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Review of positron emission tomography (PET) indications. Appropriate use criteria]
2021     Center for Drug Evaluation (CDE) [Review of international guidelines and comparative effectiveness of high cost antidiabetes drugs]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of age limits in the mammography screening programme]
2009     National Evidence-based Healthcare Collaborating Agency (NECA) [Reuse of single-use medical devices: current evidence and regulations]
2009     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Reuse of single use medical devices]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Retinal protection during eye surgery]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Retigabine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Results of the perinatal care of very premature children in the health system of the Basque Country]
2010     Andalusian Health Technology Assessment Area (AETSA) [Results from endovascular treatment in lower limb peripheral arterial disease]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Responder analyses for memantine in Alzheimer's disease - Rapid report]
2008     Committee for New Health Technology Assessment (CNHTA) [Respiratory syncytial virus, RT-nested PCR]
2021     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Respiratory rehabilitation following hospitalization related to a diagnosis of COVID-19]
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Respiratory rehabilitation following hospitalization related to a diagnosis of COVID-19 - an update]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Respiratory polygraphy for obstructive sleep apnea syndrome]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Reslizumab (severe eosinophilic asthma) - Benefit assessment according to § 35a Social Code Book V]